SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

NewAmsterdam Pharma wins EU approval for obicetrapib drugs

European Commission marketing authorizations were granted for Ubeslo and Evlarco, both containing obicetrapib. The company said these are the first global approvals for obicetrapib.

NAMS

NewAmsterdam Pharma announced European Commission marketing authorizations for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg + ezetimibe 10 mg) — the first global approvals for obicetrapib.Key Highlights:Original SEC Filing: NewAmsterdam Pharma Co N.V. [ NAMS ] - 8-K - Sep. 21, 2026This…

Related stories